Interpreting Lyme Disease Serology Results from Body Screens
Lyme serology from routine body screens should NOT be used to diagnose Lyme disease in asymptomatic individuals, as the low positive predictive value in low pre-test probability settings leads to false-positive results and inappropriate treatment. 1
Critical Context for Interpretation
The interpretation of Lyme serology is entirely dependent on clinical presentation and epidemiologic exposure—never interpret results in isolation 1, 2.
When Serology is NOT Indicated
- Asymptomatic screening: Do not order Lyme serology as part of routine body screens or health panels
- Early erythema migrans (EM): If a patient has the characteristic expanding rash (>5 cm) and lives in or traveled to an endemic area (Northeast/Upper Midwest US), diagnose clinically without serology 1
- Serology has only 30-40% sensitivity in early localized disease during the antibody "window period" 1
When Serology IS Indicated
Order testing only when:
- Patient has symptoms consistent with disseminated Lyme disease (multiple EM lesions, facial palsy, meningitis, carditis, or large-joint arthritis) 1
- Patient lives in or has traveled to endemic regions
- No EM rash is present to make clinical diagnosis
The Two-Tiered Testing Algorithm
Both tiers must be completed and positive for a confirmed diagnosis 1:
First Tier: EIA/ELISA or IFA
- Measures total IgM and IgG antibody response
- High sensitivity but lower specificity (prone to false positives from cross-reactive antibodies)
- If negative: Stop here—no serologic evidence of Lyme disease
- If positive or equivocal: Automatically proceed to second tier
Second Tier: Western Immunoblot
- Detects antibodies to specific Borrelia burgdorferi proteins
- High specificity (>95%) to reduce false positives from first tier 1
- Separate IgM and IgG blots with specific band criteria
- Only a positive Western blot confirms the diagnosis
Performance Characteristics by Disease Stage
| Disease Stage | Sensitivity | Specificity |
|---|---|---|
| Early localized (acute) | 30-40% | >95% |
| Early disseminated | 70-100% | >95% |
| Late disseminated | 70-100% | >95% |
Common Pitfalls in Body Screen Results
False Positives (The Major Problem)
In low-prevalence populations (asymptomatic screening), even tests with 95% specificity will have low positive predictive value—meaning most positive results are false 3, 4. This leads to:
- Unnecessary antibiotic treatment
- Patient anxiety and misdiagnosis
- Persistent belief in "chronic Lyme disease" despite negative confirmatory testing
IgM Interpretation Traps
- IgM can remain positive for years after treatment or infection 4, 5
- IgM positivity alone (without IgG) in late-stage disease is usually a false positive 5
- Never interpret isolated IgM as active disease without appropriate clinical context
- IgM should only be considered meaningful in disease duration <30 days 5
IgG Persistence
- IgG antibodies can persist for years after successful treatment 4
- A positive IgG does not indicate active infection or need for retreatment
- Cannot use serology to assess treatment response or "cure" 4, 6
Specific Interpretation Scenarios
Scenario 1: Positive First-Tier, Negative Western Blot
Interpretation: No serologic evidence of Lyme disease—likely false positive from cross-reactive antibodies 1
- Do not treat
- Consider alternative diagnoses
Scenario 2: Positive Two-Tier Test, No Symptoms, No Endemic Exposure
Interpretation: Likely false positive or past resolved infection 3, 6
- Do not treat asymptomatic patients
- Antibodies may persist from prior infection (even subclinical)
- Retest only if symptoms develop
Scenario 3: Positive Two-Tier Test with Compatible Symptoms
Interpretation: Confirms Lyme disease diagnosis 1
- Treat according to clinical manifestation
- Duration: 10-28 days depending on presentation 7
Scenario 4: Negative Serology with Suspected Early Lyme
Interpretation: Does not rule out early infection 1, 2
- If high clinical suspicion with EM: treat empirically
- Consider convalescent serology in 2-4 weeks if diagnosis uncertain
- Early antibiotic treatment can blunt or prevent antibody response 4, 5
Geographic Considerations
Endemic regions (where testing has higher predictive value):
- Northeast US: Connecticut to Maryland
- Upper Midwest: Wisconsin, Minnesota
- Limited West Coast areas
Non-endemic regions: Positive results have much lower positive predictive value—be especially skeptical 3, 4
Key Takeaway for Body Screens
A positive Lyme serology on a routine body screen in an asymptomatic patient should be disregarded unless there is specific clinical and epidemiologic context supporting the diagnosis. The test should never have been ordered in the first place. Do not initiate treatment based on screening results alone—this represents a fundamental misuse of serologic testing 2, 3, 6.